Search
Breast Cancer Clinical Trials in Dallas, TX
A listing of 73 Breast Cancer clinical trials in Dallas, TX actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
61 - 72 of 73
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Breast Cancer
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Dallas, Texas, currently has 73 active clinical trials seeking participants for Breast Cancer research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Hyperacusis Activities Treatment-Online Study
Recruiting
Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.
Conditions:
Hyperacusis
Tinnitus
Hearing Loss
Featured Trial
Irritability Associated with Autism (Children and Adolescents) Study
Recruiting
Become part of a clinical trial today and play a role in driving medical research forward, aiding in the discovery of groundbreaking therapies. Get rewarded for your time with monetary compensation and enjoy access to medical treatment at no charge.
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Recruiting
The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitive to pembrolizumab and cisplatin therapy. The trial will include in depth analysis of the patients' TNBC genome and phosphoproteome to evaluate HR-proficiency and deficiency, and nuclear proteins that drive NHEJ, before and upon progression with bortezomib therapy.
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas
Conditions: Breast Cancer
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
Recruiting
The purpose of this study is to determine the impact of pre-operative cryoablation, and immune checkpoint inhibition (ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") resectable breast cancer after taxane-based neoadjuvant chemotherapy.
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Breast Cancer
A Phase I Dose Escalation Study of Single Fraction Ablative Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer
Recruiting
The purpose of this phase I trial is to evaluate dose-limiting toxicity while dose escalating single-fraction preoperative S-PBI to a presumed radioablative dose over 3 cohorts, starting with 30Gy in 1 fraction and advancing to 34Gy and 38Gy in 1 fraction.
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/05/2023
Locations: University of Texas Southwestern Medical Center - Dallas, Dallas, Texas
Conditions: Breast Cancer
GammaPod Registry and Quality of Life Nomogram
Recruiting
This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
Gender:
Female
Ages:
18 years and above
Trial Updated:
09/11/2023
Locations: UTSouthwestern, Dallas, Texas
Conditions: Breast Cancer Female
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab
Recruiting
This is a phase 1/2, open-label, multi-center, first-in-human, two-stage (Part 1: dose escalation and Part 2: dose expansion) study evaluating multiple doses and schedules of intravenously (IV) administered HMBD-002, with or without pembrolizumab, in patients with advanced solid tumors (i.e., locally advanced and unresectable, or metastatic).
Gender:
All
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: UTSW Medical Center, Dallas, Texas
Conditions: Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/30/2023
Locations: Texas Oncology P.A. - Dallas, Dallas, Texas +1 locations
Conditions: Breast Cancer
CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer
Recruiting
This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple negative breast cancer, and to determine a safe dose and treatment schedule of the three drugs. This research study will also test how these treatments improve your body's immune response against the cancer.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/19/2023
Locations: Texas Oncology, P.A., Dallas, Texas +1 locations
Conditions: Metastatic Triple Negative Breast Cancer
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
Recruiting
The purpose of this study is to better understand how the immune system plays a role in fighting breast cancer and specifically research if the immune system response against breast cancer can be improved with endocrine therapy and cyclin dependent kinase inhibitor therapy in patients with hormone receptor positive breast cancer. This will be studied by collecting tumor tissue and blood samples before and after 2 weeks of study treatment with commonly used endocrine therapy and cyclin dependent... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/25/2023
Locations: Parkland Hospital, Dallas, Texas +1 locations
Conditions: Breast Cancer
IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors
Recruiting
This trial is a first-in-human, open label, multi-center, dose escalation phase 1a study followed by a disease-specific dose expansion phase 1b study to evaluate the safety, efficacy, and pharmacokinetics (PK) of IMM2902, a HER2/SIRPα bispecific mAb-Trap antibody-receptor fusion protein, in patients with HER2-expressing advanced solid tumor.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Recruiting
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Recruiting
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2023
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation, Small Cell Lung Cancer, SCLC
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
Recruiting
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types:
Triple negative breast cancer
Epithelial ovarian cancer
Non-small cell lung cancer
Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma
Small cell lung can... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/29/2022
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Gastric Adenocarcinoma, Breast Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Epithelial Ovarian Cancer, Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
61 - 72 of 73